首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1668024

CGRP 抑制劑市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、給藥途徑、最終用戶、地區和競爭進行細分，2020-2030 年預測

CGRP Inhibitor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Route of Administration, By End-User By Region and Competition, 2020-2030F

出版日期: 2025年02月28日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球 CGRP 抑制劑市值為 32.9 億美元，預計到 2030 年將達到 48.7 億美元，預測期內複合年成長率為 9.72%。全球 CGRP 抑制劑市場已成為製藥和醫療保健產業中一個充滿活力且快速發展的產業。 CGRP（降鈣素基因相關胜肽）抑制劑是一類新型藥物，旨在治療和緩解偏頭痛和叢集性頭痛等衰弱症狀。由於世界範圍內偏頭痛患病率的不斷上升以及現有治療方案的有效性有限，該市場經歷了大幅成長和創新。根據世界衛生組織 (WHO) 於 2024 年 3 月發表的文章，估計 2021 年全球 40% 的人口（約 31 億人）患有偏頭痛和其他頭痛疾病。

市場概況
預測期	2026-2030
2024 年市場規模	32.9 億美元
2030 年市場規模	48.7 億美元
2025-2030 年複合年成長率	9.72％
成長最快的領域	口服
最大的市場	北美洲

全球 CGRP 抑制劑市場擴張的關鍵促進因素之一是偏頭痛發生率的上升，影響著全球數百萬人。偏頭痛不僅會帶來難以忍受的疼痛，還會因缺勤和生產力下降而造成巨大的經濟負擔。因此，製藥公司投入大量資金進行研發，以研發 CGRP 抑制劑，該抑制劑在減少偏頭痛發作的頻率和嚴重程度方面表現出顯著的療效。此外，FDA 批准多種 CGRP 抑制劑，顯示其安全性和有效性，這也推動了市場的成長。這些批准為醫療保健提供者和患者更廣泛地採用 CGRP 抑制劑鋪平了道路。因此，市場見證了多種品牌和仿製 CGRP 抑制劑藥物的推出，為患者提供了更廣泛的選擇，並促進了市場擴張。此外，全球 CGRP 抑制劑市場的特點是製藥巨頭之間的激烈競爭，各公司不斷努力開發創新配方和給藥方法來改善患者的治療效果。此外，生物技術和神經科學的進步促進了對偏頭痛潛在機制的更好理解，從而開發出更有針對性和更有效的 CGRP 抑制劑。

主要市場促進因素

偏頭痛和叢集性頭痛盛行率上升

主要市場挑戰

治療費用高且難以取得

主要市場趨勢

新興生物相似藥和學名藥

f 該地區的個人，從而形成了一個需要 CGRP 抑制劑等有效治療的患者群體。

Global CGRP Inhibitor Market was valued at USD 3.29 Billion in 2024 and is expected to reach USD 4.87 Billion by 2030 with a CAGR of 9.72% during the forecast period. The Global CGRP Inhibitor Market has emerged as a dynamic and rapidly evolving sector within the pharmaceutical and healthcare industry. CGRP (Calcitonin Gene-Related Peptide) inhibitors represent a novel class of drugs designed to address and alleviate debilitating conditions such as migraines and cluster headaches. This market has witnessed substantial growth and innovation due to the increasing prevalence of migraine disorders worldwide and the limited effectiveness of existing treatment options. As per the World Health Organization (WHO) article published in March 2024, an estimated 40% of the global population, equivalent to approximately 3.1 billion individuals, experienced migraine and other headache disorders in 2021.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.29 Billion
Market Size 2030	USD 4.87 Billion
CAGR 2025-2030	9.72%
Fastest Growing Segment	Oral
Largest Market	North America

One of the key drivers behind the expansion of the Global CGRP Inhibitor Market is the rising incidence of migraines, affecting millions of people across the globe. Migraines not only result in excruciating pain but also lead to substantial economic burdens due to missed workdays and reduced productivity. As a result, pharmaceutical companies have invested heavily in research and development efforts to create CGRP inhibitors, which have shown remarkable efficacy in reducing the frequency and severity of migraine attacks. Furthermore, the market's growth is bolstered by the FDA approvals of various CGRP inhibitors, signaling their safety and efficacy. These approvals have paved the way for a wider adoption of CGRP inhibitors among healthcare providers and patients. As a result, the market has witnessed the launch of several branded and generic CGRP inhibitor drugs, offering a broader range of choices to patients and contributing to market expansion. Moreover, the Global CGRP Inhibitor Market is characterized by intense competition among pharmaceutical giants, with companies constantly striving to develop innovative formulations and delivery methods to improve patient outcomes. Additionally, advancements in biotechnology and neuroscience have facilitated a better understanding of the underlying mechanisms of migraine, leading to the development of more targeted and effective CGRP inhibitors.

Key Market Drivers

Rising Prevalence of Migraines and Cluster Headaches

The Global CGRP (Calcitonin Gene-Related Peptide) Inhibitor Market has witnessed a significant boost in recent years, largely attributable to the rising prevalence of migraines and cluster headaches worldwide. Migraines, characterized by intense and debilitating headaches often accompanied by nausea, vomiting, and sensitivity to light and sound, affect an ever-increasing number of individuals globally. Similarly, cluster headaches, though less common, are excruciatingly painful and tend to occur in clusters or cycles, affecting individuals' quality of life .In June 2023, during Migraine and Headache Awareness Month, the foundation introduced the "GET HEADUCATED" campaign to emphasize the importance of educating individuals and communities about the disorder. This initiative aims to mobilize the community in addressing stigma associated with the condition while fostering greater awareness, ultimately driving the adoption of treatment options.

The sheer magnitude of these disorders' impact on individuals, both in terms of physical suffering and the socioeconomic burden they impose, has prompted a growing demand for more effective treatment options. Traditional remedies, including over-the-counter pain relievers and preventive medications, often provide limited relief and are associated with various side effects, leaving patients and healthcare providers seeking alternative solutions. CGRP inhibitors have emerged as a ray of hope in this landscape, as they address the root causes of migraines and cluster headaches, offering more effective and well-tolerated treatment options.

The rising prevalence of migraines and cluster headaches has not only increased the patient pool but has also garnered attention from the pharmaceutical industry. Recognizing the immense unmet medical need and the potential market opportunity, pharmaceutical companies have ramped up their research and development efforts to create innovative CGRP inhibitor formulations. This surge in investment has resulted in the development of a diverse range of CGRP inhibitors, including monoclonal antibodies and small molecules, each designed to cater to the specific needs of patients.

Moreover, the heightened awareness of migraine and cluster headache disorders, fueled by patient advocacy groups and healthcare campaigns, has further accelerated diagnosis and treatment initiation. Patients are more informed about their condition, and healthcare providers are increasingly recognizing the potential benefits of CGRP inhibitors in providing effective and sustainable relief.

Key Market Challenges

High Treatment Costs and Accessibility Issues

CGRP inhibitors are at the forefront of migraine and cluster headache treatments due to their efficacy and novel mechanisms of action. However, their development involves extensive research, clinical trials, and biotechnological processes, making them expensive to produce. As a result, the price tag attached to CGRP inhibitors is often exceptionally high, putting them out of reach for many patients. Even when patients recognize the potential benefits of CGRP inhibitors, many face insurmountable challenges when seeking insurance coverage or reimbursement for these treatments. Insurance companies and healthcare payers may be hesitant to cover the cost of CGRP inhibitors due to their high price, requiring substantial evidence of cost-effectiveness and long-term safety. This reluctance can limit patient access, leaving them to shoulder the financial burden themselves.

The accessibility issues are further exacerbated in developing regions where healthcare infrastructure may be lacking, and patients may not have the financial means to afford these costly treatments. This disparity in access to CGRP inhibitors underscores a global healthcare divide, leaving many individuals without access to cutting-edge migraine and cluster headache therapies. High treatment costs can not only deter patients from starting CGRP inhibitor therapies but also lead to non-adherence, as some patients may ration or skip doses to make their medication last longer. This compromises the effectiveness of the treatment and may contribute to suboptimal outcomes.

Key Market Trends

Emerging Biosimilars and Generics

Emerging biosimilars and generics are playing a pivotal role in boosting the Global CGRP (Calcitonin Gene-Related Peptide) Inhibitor Market. These cost-effective alternatives to branded CGRP inhibitors are reshaping the treatment landscape for migraine and cluster headache sufferers.

Biosimilars, which are biologic drugs similar to the original CGRP inhibitors, offer comparable efficacy and safety profiles at a reduced cost. They are gaining traction in the market as patents for some branded CGRP inhibitors expire. Biosimilars present a win-win situation, allowing patients to access CGRP inhibitor therapies at more affordable prices while increasing market competitiveness. Generics, on the other hand, are non-branded versions of the original CGRP inhibitors. As patents expire, generic versions become available, offering a more budget-friendly option for patients. This trend is particularly significant in healthcare systems where cost considerations heavily influence treatment decisions.

The emergence of biosimilars and generics addresses the issue of treatment affordability and accessibility, breaking down barriers that once hindered patient access to CGRP inhibitors. As competition increases, the prices of these medications are likely to decrease, making CGRP inhibitor therapies available to a broader patient population, including those with limited insurance coverage or residing in regions with constrained healthcare resources. Moreover, the presence of biosimilars and generics encourages pharmaceutical companies to stay competitive by continuously improving their products and services. This competitive environment can drive innovation and lead to the development of more efficient and cost-effective CGRP inhibitor therapies.

f individuals in the region, creating a substantial patient pool in need of effective treatments like CGRP inhibitors.

Key Market Players

Eli Lilly and Company
Pfizer Inc.
Teva Pharmaceutical Industries Ltd
AbbVie Inc.
Amgen Inc
Novartis AG
Allergan
Biohaven Pharmaceutical Holding Company Ltd.
Sun Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global CGRP Inhibitor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CGRP Inhibitor Market, By Treatment:

Preventive
Acute

CGRP Inhibitor Market, By Route of Administration:

Oral
Nasal
Intravenous

CGRP Inhibitor Market, By End-User:

Hospitals
Pharmacies
Specialty Clinics

CGRP Inhibitor Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CGRP Inhibitor Market.

Available Customizations:

Global CGRP Inhibitor Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CGRP Inhibitor Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment (Preventive, Acute)
- 5.2.2. By Route of Administration (Oral, Nasal, Intravenous)
- 5.2.3. By End-User (Hospitals, Pharmacies, Specialty Clinics)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America CGRP Inhibitor Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment
- 6.2.2. By Route of Administration
- 6.2.3. By End-User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States CGRP Inhibitor Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By End-User
- 6.3.2. Canada CGRP Inhibitor Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By End-User
- 6.3.3. Mexico CGRP Inhibitor Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By End-User

7. Europe CGRP Inhibitor Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment
- 7.2.2. By Route of Administration
- 7.2.3. By End-User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany CGRP Inhibitor Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By End-User
- 7.3.2. United Kingdom CGRP Inhibitor Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By End-User
- 7.3.3. Italy CGRP Inhibitor Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By End-User
- 7.3.4. France CGRP Inhibitor Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Treatment
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By End-User
- 7.3.5. Spain CGRP Inhibitor Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Treatment
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By End-User

8. Asia-Pacific CGRP Inhibitor Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment
- 8.2.2. By Route of Administration
- 8.2.3. By End-User
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China CGRP Inhibitor Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By End-User
- 8.3.2. India CGRP Inhibitor Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By End-User
- 8.3.3. Japan CGRP Inhibitor Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By End-User
- 8.3.4. South Korea CGRP Inhibitor Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Treatment
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By End-User
- 8.3.5. Australia CGRP Inhibitor Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By End-User

9. South America CGRP Inhibitor Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment
- 9.2.2. By Route of Administration
- 9.2.3. By End-User
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil CGRP Inhibitor Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By End-User
- 9.3.2. Argentina CGRP Inhibitor Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By End-User
- 9.3.3. Colombia CGRP Inhibitor Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By End-User

10. Middle East and Africa CGRP Inhibitor Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Treatment
- 10.2.2. By Route of Administration
- 10.2.3. By End-User
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa CGRP Inhibitor Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Treatment
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By End-User
- 10.3.2. Saudi Arabia CGRP Inhibitor Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Treatment
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By End-User
- 10.3.3. UAE CGRP Inhibitor Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Treatment
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By End-User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Eli Lilly and Company
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Pfizer Inc.
14.3. Teva Pharmaceutical Industries Ltd
14.4. Amgen Inc
14.5. Novartis AG
14.6. Allergan
14.7. Biohaven Pharmaceutical Holding Company Ltd.
14.8. Sun Pharmaceutical Industries Ltd.